Co-Authors
This is a "connection" page, showing publications co-authored by Paul Bastard and Jean-Laurent Casanova.
Connection Strength
6.804
-
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021 08 19; 6(62).
Score: 0.963
-
Insufficient type I IFN immunity underlies life-threatening COVID-19 pneumonia. C R Biol. 2021 Jun 21; 344(1):19-25.
Score: 0.952
-
Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J Exp Med. 2021 04 05; 218(4).
Score: 0.938
-
Interferon-ß Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2. J Clin Immunol. 2021 07; 41(5):931-933.
Score: 0.936
-
Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 10 23; 370(6515).
Score: 0.904
-
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021 08 19; 6(62).
Score: 0.241
-
Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021 07 05; 218(7).
Score: 0.239
-
IFN-a2a Therapy in Two Patients with Inborn Errors of TLR3 and IRF3 Infected with SARS-CoV-2. J Clin Immunol. 2021 01; 41(1):26-27.
Score: 0.230
-
Correction to: IFN-a2a Therapy in Two Patients with Inborn Errors of TLR3 and IRF3 Infected with SARS-CoV-2. J Clin Immunol. 2021 Jan; 41(1):28.
Score: 0.230
-
Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation. Med (N Y). 2020 Dec 18; 1(1):14-20.
Score: 0.230
-
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020 10 23; 370(6515).
Score: 0.226
-
Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med. 2021 09 22; 13(612):eabh2624.
Score: 0.060
-
Correction: Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. J Exp Med. 2021 Oct 04; 218(10).
Score: 0.060
-
Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients. Clin Transl Immunology. 2021; 10(8):e1327.
Score: 0.060
-
Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19. Immunol Cell Biol. 2021 10; 99(9):917-921.
Score: 0.060
-
Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. J Exp Med. 2021 10 04; 218(10).
Score: 0.060
-
Association of rare predicted loss-of-function variants of influenza-related type I IFN genes with critical COVID-19 pneumonia. J Clin Invest. 2021 08 02; 131(15).
Score: 0.060
-
Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-ß. J Clin Immunol. 2021 10; 41(7):1425-1442.
Score: 0.059
-
Atypical Inflammatory Syndrome Triggered by SARS-CoV-2 in Infants with Down Syndrome. J Clin Immunol. 2021 10; 41(7):1457-1462.
Score: 0.059
-
Polyclonal expansion of TCR Vbeta 21.3+ CD4+ and CD8+ T cells is a hallmark of Multisystem Inflammatory Syndrome in Children. Sci Immunol. 2021 05 25; 6(59).
Score: 0.059
-
Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma. J Clin Immunol. 2021 08; 41(6):1169-1171.
Score: 0.059
-
Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med. 2021 06; 47(6):704-706.
Score: 0.059
-
Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia. J Clin Immunol. 2021 04; 41(3):536-544.
Score: 0.058